TRCT
TVRD

Tower Research Capital (TRC)’s Tvardi Therapeutics TVRD Stock Holding History

Tower Research Capital (TRC)’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11K Buy
3,462
+953
+38% +$3.73K ﹤0.01% 3861
2025
Q4 		$10.8K Buy
2,509
+2,158
+615% +$19.3K ﹤0.01% 3701
2025
Q3 		$13.7K Buy
351
+248
+241% +$7.06K ﹤0.01% 3663
2025
Q2 		$2.4K Buy
+103
New +$2.44K ﹤0.01% 4656
2025
Q1 		– Sell
-127
Closed -$2.34K – 5971
2024
Q4 		$2.34K Sell
127
-20
-14% -$218 ﹤0.01% 4861
2024
Q3 		$1.63K Sell
147
-479
-77% -$5.62K ﹤0.01% 5130
2024
Q2 		$5.81K Buy
626
+309
+97% +$7.37K ﹤0.01% 4649
2024
Q1 		$10.4K Sell
317
-100
-24% -$2.59K ﹤0.01% 3702
2023
Q4 		$11.1K Buy
417
+187
+81% +$7.74K ﹤0.01% 4157
2023
Q3 		$13.9K Sell
230
-22
-9% -$2.06K ﹤0.01% 3738
2023
Q2 		$25.7K Buy
252
+136
+117% +$18.7K ﹤0.01% 3167
2023
Q1 		$20K Sell
116
-376
-76% -$126K ﹤0.01% 3460
2022
Q4 		$191K Buy
492
+149
+43% +$56.6K 0.01% 1333
2022
Q3 		$116K Buy
343
+155
+82% +$56.1K ﹤0.01% 2445
2022
Q2 		$62K Buy
188
+20
+12% +$7.02K ﹤0.01% 2691
2022
Q1 		$73K Sell
168
-44
-21% -$18.1K ﹤0.01% 2436
2021
Q4 		$93K Sell
212
-285
-57% -$143K ﹤0.01% 2276
2021
Q3 		$277K Buy
497
+414
+499% +$208K 0.01% 1495
2021
Q2 		$43K Sell
83
-26
-24% -$16.5K ﹤0.01% 3155
2021
Q1 		$85K Buy
109
+1
+0.9% +$685 ﹤0.01% 2714
2020
Q4 		$59K Sell
108
-566
-84% -$297K ﹤0.01% 2941
2020
Q3 		$308K Buy
674
+501
+290% +$291K ﹤0.01% 2161
2020
Q2 		$106K Buy
+173
New +$95.5K ﹤0.01% 2403
2020
Q1 		– Sell
-180
Closed -$104K – 4056
2019
Q4 		$104K Buy
180
+177
+5,900% +$124K 0.01% 917
2019
Q3 		$2K Buy
+3
New +$2.49K ﹤0.01% 3755
2019
Q2 		– Sell
-11
Closed -$8K – 4412
2019
Q1 		$8K Buy
+11
New +$6.58K ﹤0.01% 2830
2018
Q3 		– Sell
-1
Closed -$1K – 4321
2018
Q2 		$1K Sell
1
-2
-67% -$1.02K ﹤0.01% 3525
2018
Q1 		$1K Buy
+3
New +$1.46K ﹤0.01% 3118
2017
Q2 		– Sell
-19
Closed -$13K – 3567
2017
Q1 		$13K Sell
19
-28
-60% -$15K ﹤0.01% 1610
2016
Q4 		$16K Sell
47
-111
-70% -$35.6K ﹤0.01% 2343
2016
Q3 		$47K Buy
+158
New +$34.2K ﹤0.01% 1186
2016
Q2 		– Sell
-89
Closed -$20K – 5072
2016
Q1 		$20K Buy
89
+86
+2,867% +$25.7K ﹤0.01% 1360
2015
Q4 		$2K Sell
3
-81
-96% -$44.5K ﹤0.01% 3834
2015
Q3 		$43K Buy
84
+76
+950% +$50.9K ﹤0.01% 1130
2015
Q2 		$4K Sell
8
-26
-76% -$10K ﹤0.01% 3417
2015
Q1 		$12K Sell
34
-20
-37% -$7.57K ﹤0.01% 2664
2014
Q4 		$19K Buy
54
+50
+1,250% +$16.1K ﹤0.01% 1644
2014
Q3 		$1K Buy
+4
New +$1.64K ﹤0.01% 4177
2014
Q2 		– Sell
-102
Closed -$68K – 4728
2014
Q1 		$68K Buy
+102
New +$60.3K 0.01% 899

Other funds holding TVRD

SPC
Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AFG
American Financial Group Cincinnati, Ohio $270M AUM 3.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SAM
Silvercrest Asset Management New York $13.8B AUM 28.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DWAM
Duncan Williams Asset Management Memphis, Tennessee $444M AUM 24.78% 1-Year Est. Return

Tower Research Capital (TRC)'s TVRD Position: Q1 2026 in Review

Tower Research Capital (TRC) increased its Tvardi Therapeutics (TVRD) stake by 38% in Q1 2026, buying an estimated $3.73K and bringing the position to 3,462 shares worth $11K. The position accounts for ﹤0.01% of the portfolio, ranked #3861.

Tower Research Capital (TRC) first reported a position in TVRD in Q1 2014 and has held it in 39 quarters since. The position peaked at $308K in Q3 2020. 67 funds tracked by Wall St. Rank hold TVRD as of Q1 2026.

  • Tower Research Capital (TRC) held 3,462 shares of Tvardi Therapeutics worth $11K as of Q1 2026.
  • Tower Research Capital (TRC) bought 953 Tvardi Therapeutics shares in Q1 2026, an estimated $3.73K.
  • Tvardi Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3861 holding.
  • Tower Research Capital (TRC) first reported a position in Tvardi Therapeutics in Q1 2014 and has held it in 39 quarters since.
  • Tower Research Capital (TRC)'s Tvardi Therapeutics position peaked at $308K in Q3 2020.
  • 67 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.